GLP-1 and Kidney Health: What the FLOW Trial Really Found

The FLOW trial was a large study published in the *New England Journal of Medicine* in 2024 that tested whether semaglutide (the active ingredient in Ozempic and Wegovy) could protect the kidneys. Researchers followed more than 3,500 people with type 2 diabetes and chronic kidney disease (CKD) — a condition where the kidneys slowly lose their ability to filter waste from the blood.

The results were strong enough that the trial was stopped early. Semaglutide reduced the risk of major kidney events — things like kidney failure, a large drop in kidney function, or death from kidney or heart causes — by 24% compared with a placebo. The medication also lowered the risk of death from cardiovascular causes and slowed the yearly decline in kidney filtering rate.

This matters because CKD affects roughly 1 in 7 adults, and for decades doctors had very few tools to slow it down. FLOW put GLP-1 medications on the map as a potential kidney-protecting therapy, not just a weight or blood-sugar drug. If you want the bigger picture on how these drugs work in the body, our guide on [how GLP-1 medications actually work](/blog/how-do-glp1-medications-actually-work-mechanism) breaks down the mechanism step by step.

GLP-1 medications appear to protect the kidneys through several overlapping pathways, and interestingly, not all of them depend on weight loss. Researchers believe the benefit is partly direct — acting on the kidney itself — and partly indirect, by improving the things that damage kidneys over time.

First, GLP-1s lower blood pressure modestly. High blood pressure is one of the two leading causes of kidney damage, so even a small, sustained drop eases the strain on the delicate filtering units called nephrons. Second, they reduce inflammation and oxidative stress in blood vessels, including the tiny vessels inside the kidney. Third, by improving blood sugar control, they reduce the high-glucose environment that scars kidney tissue in diabetes.

There is also evidence that GLP-1s reduce albuminuria — protein leaking into the urine, which is an early warning sign of kidney trouble. In FLOW, semaglutide slowed the rise of this marker. Because some of the protection showed up faster than weight loss alone could explain, scientists suspect the drug has effects on kidney blood flow and pressure that are somewhat independent of the number on the scale. The same anti-inflammatory, blood-vessel benefits are why GLP-1s also help the heart, as covered in our piece on [GLP-1s and heart health from the SELECT trial](/blog/glp1-heart-health-select-trial-cardiovascular-benefits).

The people who benefited most in FLOW were those with type 2 diabetes and established chronic kidney disease — the exact group studied. If you have both conditions, the evidence for kidney protection is now quite strong, and semaglutide is increasingly discussed as part of a kidney-protective regimen alongside other proven medications.

It's important to be honest about what we *don't* yet know. FLOW did not study people who take GLP-1s purely for weight loss without diabetes or kidney disease. So while the biological reasons to expect some benefit are reasonable, we can't promise the same 24% reduction to someone with healthy kidneys taking the medication for weight management. What we can say is that the safety signal for kidneys was reassuring across the board.

People carrying extra visceral fat — the deep abdominal fat that surrounds organs — may have particular reason for interest, because that fat type drives inflammation and metabolic strain. Our article on [GLP-1 and visceral fat](/blog/glp1-and-visceral-fat-in-menopause-targeting-belly-fat) explains why losing this specific fat matters for overall organ health. If you have diabetes, CKD, high blood pressure, or a strong family history of kidney disease, this is a conversation worth having with your clinician.

The main kidney-related risk with GLP-1 medications is indirect and short-term: dehydration. GLP-1s commonly cause nausea, vomiting, or diarrhea, especially in the first weeks or after a dose increase. If you lose a lot of fluid and don't replace it, your blood volume drops, and your kidneys can temporarily struggle — a state called acute kidney injury (AKI). This is usually reversible once you rehydrate.

The good news is that this risk is largely preventable. Sipping fluids steadily, not skipping meals entirely, and slowing down dose increases if side effects are severe all help. If you ever notice you're urinating much less than usual, feel very dizzy on standing, or can't keep fluids down for more than a day, that's a signal to contact your care team. Our guide on [hydration while on GLP-1s](/blog/hydration-on-glp1-during-menopause-why-so-thirsty) has practical strategies for staying ahead of it.

Outside of dehydration, the trial data has been reassuring — GLP-1s did not appear to cause direct kidney damage, and in FLOW they clearly protected kidney function over the long term. As with any medication, the picture is about balancing well-established benefits against a manageable, mostly preventable short-term caution.

If you take a GLP-1 medication or are considering one, the FLOW findings are genuinely encouraging news — but they don't require you to do anything dramatic on your own. The most useful steps are simple. Stay well hydrated, particularly in the first months and after dose increases. Keep up with routine blood and urine tests your clinician orders; kidney function is measured through an eGFR blood test and a urine albumin test, and tracking them over time tells the real story.

If you have diabetes or diagnosed kidney disease, ask your clinician directly whether the FLOW results change their thinking about your treatment plan. GLP-1s are now part of the toolkit for kidney protection, often alongside other proven medicines. If you're taking a GLP-1 mainly for weight, you can view kidney benefits as a plausible bonus rather than a guarantee.

Finally, remember that kidney health is built on fundamentals that no medication replaces: controlling blood pressure, not smoking, staying active, and managing blood sugar. GLP-1s are a powerful new addition, not a substitute. Have questions about how this applies to your own situation?